The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.

Inclusion Criteria:

• Malignant solid tumor for which there is no currently approved treatment
• Adequate bone marrow, liver, cardiac, and kidney function

Exclusion Criteria:

• Cardiac disease
• Anticancer therapy within 4-6 weeks (depending on therapy)
• Pregnant or breast-feeding

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.